Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab +/- Ciprofloxacin for Perianal Fistulas in Crohn's Disease
NCT00736983Phase 3Completed
- Sponsor
- Foundation for Liver Research
- Start
- Sep 2008
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Adalimumab + Ciprofloxacin with Adalimumab + Placebo (2 arms). Primary endpoint: Reduction of 50% or more in the number of draining perianal fistulas at 12 weeks. Started Sep 2008; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00736983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00736983.